Key Takeaways
- Triple-digit revenue scale-up, now profitable: Total income hit ₹35.78 cr in Q3 FY26 vs ₹9.38 cr a year ago, and the company swung to a ₹5.15 cr PAT from a loss, driven by higher API volumes and operating leverage.
- Capacity is the binding constraint: Existing facilities are over 90% utilized, capping organic growth at 15–20%, which is why the Apiqo Organic acquisition and a greenfield expansion were both announced this quarter.
- FY27 guidance held, called conservative: Management reiterated ₹370–380 cr consolidated revenue for FY27 and believes the result will be "much better than that," underpinned by new API launches and the Apiqo and Bizotic integrations.
- The balance sheet is healing: 35–40% of overdue H1 receivables have been collected, customer payment terms are being tightened, and working capital days are targeted to fall from 180–185 to 150–160 next year.
- What to watch next quarter: Validation progress on the two molecules due around June–July 2026, the organic expansion plan update promised by end of March, and any early revenue contribution from Apiqo.
The Capacity Inflection: Acquisitions & Greenfield
- Apiqo Organic closed: The acquisition adds backward integration and substantial fresh capacity, with its own product range and existing customer contracts already in place.
- Bizotic Life Science proposed: This acquisition will handle domestic customers and products without regulatory requirements, freeing Anlon's constrained facility for regulated export business.
- Greenfield expansion sanctioned: A new facility for Anlon (1,200–1,300 MTPA) and organic expansion for Apiqo (500–600 MTPA) were announced; execution starts 1 April 2026 with a target completion of 31 March 2027.
- Funding mix: ₹40–50 cr from routine cash flow, ₹50–60 cr from bank debt, with peak debt-to-equity expected around 0.5 to 0.55. No further equity dilution is planned.
- Subsidiary consolidation path: Management intends to make both Apiqo and Bizotic 100% subsidiaries before the end of next financial year via a share swap to existing shareholders, not a cash transaction, with a merger to follow within 3–4 months.
Punit Kumar Rasadia: "We have planned that before end of the next financial year, we'll do it the 100 percent subsidiary."
Revenue Trajectory & Seasonality
- Q3 vs Q2 decline explained: Revenue fell sequentially because December brings Christmas holidays for overseas customers, so most shipments are held; management urged investors to compare H1 vs H2 rather than quarter-to-quarter.
- FY26 guidance intact: The company is targeting approximately ₹170–180 cr from existing products (ketoprofen, loxoprofen, intermediates), with no spare capacity for new molecules at the current facility.
- FY27 build-up: Anlon contributes ₹170–180 cr from its existing portfolio, Apiqo adds its own contracted product range, and Bizotic layers on domestic volumes shifted out of Anlon due to capacity constraints.
- FY28 ambition: Management expects at least ₹650–700 cr consolidated, though it declined to commit to a peak revenue number after all expansion, calling it "very early" and promising an update after H1 next year.
- Concentration risk: Approximately 30–35% of revenue comes from loxoprofen and its intermediate, plus ketoprofen and its intermediate, a dependency the new API launches are designed to dilute.
Punit Kumar Rasadia: "we are believing that, result would be much better than what, 370 to 380 Crores."
New Product Pipeline & Therapeutic Diversification
- 6 or 7 new APIs in FY27: These molecules have already been filed and validated but were not commercialized due to the capacity bottleneck; the greenfield and acquisitions unlock them.
- 2 validations due Q1 FY27: One molecule's validation quantity was dispatched in February 2026, with two more expected around June–July 2026.
- Loxoprofen gel and spray: Formulation development has started, targeting the Indian market as a competitive alternative to Volini gel; DCGI approval is expected in the next-to-next financial year.
- Portfolio breadth: Existing products already span cardiac (ticagrelor, ranolazine), arthritis (tofacitinib), and urology (silodosin); CKD alpha-keto analog and nutraceutical products contribute roughly 10–15% of revenue.
- Biosimilar PLI opportunity: The government announced a ₹10,000 cr PLI scheme for biosimilar products; the company will apply and expects to be eligible.
Punit Kumar Rasadia: "we are one of the largest manufacturer, and we are the only Indian manufacturer. So we'll have the, some kind of, first..."
Margins, Cash Flow & Balance Sheet
- 9M FY26 profitability: EBITDA margin improved to 26.84%, and PAT grew significantly to ₹18.02 cr, demonstrating operating leverage on the scaled-up revenue base of ₹121.32 cr.
- Working capital turning: 35–40% of overdue H1 payments have been cleared, and changes to customer payment terms have been implemented to drive further improvement.
- Targets: Working capital days are expected to reach 180–185 by FY26 end and 150–160 next year; positive operating cash flow is targeted by FY27 end, with an effort to achieve it by H1 FY27 if customer payment term changes are accepted.
- Bizotic margin profile: The acquired entity is expected to deliver 30–35% EBITDA margins, which will blend into the consolidated P&L.
Competitive Positioning & Adjacent Bets
- Peptide manufacturing: The company is evaluating a greenfield facility for GLP-1 and cosmetic peptides, though no timeline has been set.
- AI healthcare project: An in-house IT team is restarting a project originally developed in 2014–15 for a healthcare distribution ecosystem with an AI-based agent on patients' mobile phones; shareholders will be informed once there is a development.
- Level playing field thesis: Management argued that while larger peers may have stronger financial resources, all Indian pharma companies are at roughly the same starting point on new technologies like biosimilars, peptides, and AI, creating equal opportunity.
Punit Kumar Rasadia: "all the pharma company in India are almost at the same level. See, they are maybe stronger in financial or resources, but at the new technology, what world is changing for biosimilar, peptide, AI, so all the companies are at the same level. So everyone is, having the, equal opportunities."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 consolidated revenue | ₹170–180 cr (existing products) to ~₹180–200 cr consolidated | FY26 |
| FY27 consolidated revenue | ₹370–380 cr, described as "very much conservative" | FY27 |
| FY28 consolidated revenue | At least ₹650–700 cr | FY27–28 |
| 2 molecule validations | Expected around June–July 2026 | Q1 FY27 |
| Greenfield expansion completion | Operational by 31 March 2027 | By 31 March 2027 |
| Apiqo & Bizotic become 100% subsidiaries | Via share swap to existing shareholders | Before end of next financial year |
| Merger of subsidiaries | Cleared within 3–4 months of becoming 100% subsidiaries | After 100% subsidiary step |
| New API launches | 6 or 7 new APIs commercialized | Next financial year |
| Working capital days | 180–185 days by FY26 end, 150–160 days next year | FY26 end / next year |
| Positive operating cash flow | Achieved by FY27 end, attempt by H1 FY27 if payment terms accepted | H1 FY27 to FY27 end |
| Peak debt-to-equity | ~0.5 to 0.55 | During expansion phase |
| Organic expansion plan update | Planning update expected | By end of March 2026 |
| Loxoprofen gel/spray DCGI approval | Expected approval | Next-to-next financial year |
| Peak revenue after all expansion | Commitment deferred; update promised after H1 next year | After H1 next year |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Total income | ₹35.78 cr, vs ₹9.38 cr in Q3 FY25 |
| EBITDA | ₹12.54 cr, margin 35.06% |
| PAT | ₹5.15 cr, vs a loss in Q3 FY25 |
| Total income (9M FY26) | ₹121.32 cr, vs ₹71.49 cr in 9M FY25 |
| EBITDA (9M FY26) | ₹32.56 cr, margin 26.84% |
| PAT (9M FY26) | ₹18.02 cr |
| FY26 revenue guidance | ₹190–200 cr consolidated, comprising ₹160–170 cr from Anlon and ₹20–25 cr from Apiqo |
| FY27 revenue guidance | ₹370–380 cr consolidated, comprising ₹170–180 cr from Anlon, ₹125–130 cr from Apiqo, and ₹75–80 cr from Bizotic |
| 3-year revenue CAGR target | ~30% |
| Blended consolidated EBITDA margin | 30–33%, sustainable across all 3 facilities; Anlon at 35%, Apiqo at ~30%, Bizotic expected at 30–35% |
| Combined installed capacity | 1,400–1,600 metric tons per annum across 3 facilities |
| Existing Anlon facility utilization | More than 90%, effectively fully utilized |
| Apiqo Organics utilization | 80–85% |
| Bizotic utilization | 50–55% |
| Order book for next year (existing plant) | ₹180–190 cr |
| Apiqo confirmed order book for next year | ₹125–130 cr |
| Working capital days | 290 days currently; target 180–185 days by FY26 end and 150–160 days next year |
| DMF filings | 21 filed; at least 6–7 key molecules expected to be commercialized in next financial year |
| CDMO molecules under development | 3 molecules for 2 global innovator companies; 1 validation quantity dispatched, 2 expected by Q1 FY27 |
| Greenfield expansion planned capacity | 1,200–1,300 metric tons per annum for Anlon, ~500–600 for Apiqo |
| Greenfield expansion CapEx | ₹100–120 cr, funded by ₹40–50 cr internal cash flow and ₹50–60 cr bank loan; target debt-to-equity ~0.5–0.55 |
| Revenue concentration from loxoprofen and ketoprofen | 30–35% of revenue; loxoprofen expected at 25–30% in FY27 |
| New APIs planned for launch in FY27 | ~7 new APIs across additional therapeutic categories |
| Gestation period for CDMO molecule to commercial revenue | Minimum 3–4 years |
| KSM import dependence on China | None; all KSM sourced indigenously from domestic suppliers |